From Health Impact News:

Since I am not a tennis fan and have not followed Djokovic all that closely, I do not know if in his interviews he prefaces his negative comments about the COVID-19 vaccine mandates with the obligatory “I am not an anti-vaxxer,” but if this news report originally from Reuter’s is correct, he is most definitely not only pro-Big Pharma, but is looking to get a piece of the pie in COVID-19 treatments as well.

ZeroHedge goes on to report that Djokovic earns more income outside of tennis than he does as a professional tennis player, so it would make sense that he could have potentially given up his chance at defending his title at the Australian Open to be able to cash in on a larger financial windfall down the road for his drug company, by capitalizing on his stance against the mandates for COVID-19 shots.

---

From January 19, 2022, ZeroHedge News published a report on Novak Djokovic revealing that he “owns 80% stake in a Biotech firm working on COVID cure,” based on a Reuter’s story.

Since being deported from Australia last week, men’s tennis champion Novak Djokovic has returned to Belgrade, where he lives with his family.

Having inadvertently (or not) become the locus of the international debate about mandatory vaccinations, Reuters reported that Djokovic and his wife hold a combined 80% stake in Danish biotech firm QuantBioRes, which is working on developing a cure for SARS-CoV-2.

QuantBioRes boss Ivan Loncarevic has described himself as an entrepreneur, he reportedly said the tennis player’s acquisition of the 80% stake was made in June 2020, but declined to say how much Djokovic shelled out for his stake.

The firm said the company had about a dozen researchers working in Denmark, Australia and Slovenia. According to the Danish company register, Djokovic and his wife Jelena own 40.8% and 39.2% of QuantBioRes, respectively.

Copenhagen-based QuantBioRes is aiming to develop a ‘peptide’ treatment against Covid-19 which would inhibit the virus from infecting human cells. Later this year, the company expects to launch clinical trials in the UK; it has around a dozen researchers working in Denmark, Australia, and Slovenia, Loncarevic explained. (Source.)